Pharmacotherapy for the core symptoms of autism spectrum disorder.

IF 4.7 3区 生物学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY
Peiying Tan, Xiaolin Shen, Lizhang Zeng, Xuchu Weng, Hongyan Geng
{"title":"Pharmacotherapy for the core symptoms of autism spectrum disorder.","authors":"Peiying Tan, Xiaolin Shen, Lizhang Zeng, Xuchu Weng, Hongyan Geng","doi":"10.1631/jzus.B2300864","DOIUrl":null,"url":null,"abstract":"<p><p>Autism spectrum disorder (ASD) is a range of neurodevelopmental diseases characterized by social dysfunction and stereotypic behaviors. The etiology of ASD remains largely unexplored, resulting in a diverse array of described clinical manifestations and varying degrees of severity. Currently, there are no drugs approved by a supervisory organization that can effectively treat the core symptoms of ASD. Childhood and adolescence are crucial stages for making significant achievements in ASD treatment, necessitating the development of drugs specifically for these periods. Based on the drug targets and mechanisms of action, it can be found that atypical psychotropic medications, anti-inflammatory and antioxidant medications, hormonal medications, ion channel medications, and gastrointestinal medications have shown significant improvement in treating the core symptoms of ASD in both children and adolescents. In addition, comparisons of drugs within the same category regarding efficacy and safety have been made to identify better alternatives and promote drug development. While further evaluation of the effectiveness and safety of these medications is needed, they hold great potential for widespread application in the clinical treatment of the principal symptoms of ASD.</p>","PeriodicalId":17797,"journal":{"name":"Journal of Zhejiang University SCIENCE B","volume":"25 11","pages":"956-971"},"PeriodicalIF":4.7000,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11634452/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Zhejiang University SCIENCE B","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1631/jzus.B2300864","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Autism spectrum disorder (ASD) is a range of neurodevelopmental diseases characterized by social dysfunction and stereotypic behaviors. The etiology of ASD remains largely unexplored, resulting in a diverse array of described clinical manifestations and varying degrees of severity. Currently, there are no drugs approved by a supervisory organization that can effectively treat the core symptoms of ASD. Childhood and adolescence are crucial stages for making significant achievements in ASD treatment, necessitating the development of drugs specifically for these periods. Based on the drug targets and mechanisms of action, it can be found that atypical psychotropic medications, anti-inflammatory and antioxidant medications, hormonal medications, ion channel medications, and gastrointestinal medications have shown significant improvement in treating the core symptoms of ASD in both children and adolescents. In addition, comparisons of drugs within the same category regarding efficacy and safety have been made to identify better alternatives and promote drug development. While further evaluation of the effectiveness and safety of these medications is needed, they hold great potential for widespread application in the clinical treatment of the principal symptoms of ASD.

自闭症谱系障碍核心症状的药物治疗
自闭症谱系障碍(ASD)是一系列以社交功能障碍和刻板行为为特征的神经发育疾病。ASD的病因在很大程度上仍未被探索,导致各种各样的临床表现和不同程度的严重程度。目前,还没有得到监管机构批准的能够有效治疗ASD核心症状的药物。儿童和青少年是ASD治疗取得重大成就的关键阶段,因此需要开发专门针对这些时期的药物。从药物作用靶点和作用机制来看,非典型精神药物、抗炎抗氧化药物、激素药物、离子通道药物和胃肠道药物在治疗儿童和青少年ASD核心症状方面均有显著改善。此外,还对同一类别药物的疗效和安全性进行了比较,以确定更好的替代品并促进药物开发。虽然需要进一步评估这些药物的有效性和安全性,但它们在ASD主要症状的临床治疗中具有广泛应用的巨大潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Zhejiang University SCIENCE B
Journal of Zhejiang University SCIENCE B 生物-生化与分子生物学
CiteScore
8.70
自引率
13.70%
发文量
2125
审稿时长
3.0 months
期刊介绍: Journal of Zheijang University SCIENCE B - Biomedicine & Biotechnology is an international journal that aims to present the latest development and achievements in scientific research in China and abroad to the world’s scientific community. JZUS-B covers research in Biomedicine and Biotechnology and Biochemistry and topics related to life science subjects, such as Plant and Animal Sciences, Environment and Resource etc.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信